ADAP

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company headquartered in Abingdon, UK, dedicated to developing innovative T-cell therapies targeting solid tumors. With a focus on harnessing the power of the immune system, Adaptimmune leverages its proprietary SPEAR T-cell platform to design personalized therapies aimed at improving patient outcomes. The company operates primarily within the United States and the United Kingdom, positioning itself at the forefront of immuno-oncology advancements. As it progresses through key clinical trials, Adaptimmune is committed to addressing the significant unmet medical needs of cancer patients through its cutting-edge therapeutic solutions.